Neuroinflammation-associated MiR-106a-5p Serves As a Biomarker for the Diagnosis and Prognosis of Acute Cerebral Infarction

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2023 Jun 27

PMID 37369997

Authors

Wei Du

Lingyan Fan

Juan Du

Affiliations

Soon will be listed here.

Abstract

Background: Acute cerebral infarction (ACI) is a common cerebrovascular disease. Previous studies have shown that some abnormally expressed microRNAs (miRNAs) play important roles in ACI. This study aimed to investigate the role of miR-106a-5p in the diagnosis and prognosis of ACI patients, and analyze the regulatory potential of miR-106a-5p on the inflammation of BV-2 microglial cells.

Method: Serum and cerebrospinal fluid (CSF) samples were collected from 98 ACI patients, and the expression of serum miR-106a-5p was analyzed using qRT-PCR. A receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of miR-106a-5p. The association of miR-106a-5p with ACI prognosis was evaluated using the logistic analysis. In vitro experiments were performed in BV-2 cells by oxygen glucose deprivation (OGD) treatment, and the effects of miR-106a-5p on BV-2 inflammation were assessed using an enzyme linked immunosorbent assay (ELISA).

Result: It was observed that miR-106a-5p was significantly upregulated in the serum and CSF of ACI patients (all P < 0.001), and had considerable diagnostic accuracy. The highest serum miR-106a-5p was observed in severe ACI cases, and miR-106a-5p expression was significantly increased in unfavorable prognosis patients. Serum and CSF expression of miR-106a-5p was positively correlated with proinflammatory cytokines in ACI patients, and the inflammation of OGD-induced BV-2 cells was suppressed by miR-106a-5p reduction.

Conclusion: MiR-106a-5p is overexpressed in ACI patients and may serve as a diagnostic and prognostic biomarker for ACI. Furthermore, miR-106a-5p may be involved in ACI progression by regulating neuroinflammation.

Citing Articles

Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma.

Ali E, Ahmed M, Shawki M, El Arab L, Khalifa M, Swellam M Sci Rep. 2025; 15(1):1933.

PMID: 39809835 PMC: 11733229. DOI: 10.1038/s41598-024-83800-x.

References

Kim J, Jung K, Chu K, Lee S, Ban J, Moon J . Atherosclerosis-Related Circulating MicroRNAs as a Predictor of Stroke Recurrence. Transl Stroke Res. 2015; 6(3):191-7. DOI: 10.1007/s12975-015-0390-1. View

Cuevas A, Saavedra N, Cavalcante M, Salazar L, Abdalla D . Identification of microRNAs involved in the modulation of pro-angiogenic factors in atherosclerosis by a polyphenol-rich extract from propolis. Arch Biochem Biophys. 2014; 557:28-35. DOI: 10.1016/j.abb.2014.04.009. View

Ono H, Nishijima Y, Ohta S, Sakamoto M, Kinone K, Horikosi T . Hydrogen Gas Inhalation Treatment in Acute Cerebral Infarction: A Randomized Controlled Clinical Study on Safety and Neuroprotection. J Stroke Cerebrovasc Dis. 2017; 26(11):2587-2594. DOI: 10.1016/j.jstrokecerebrovasdis.2017.06.012. View

Zhang W, Cheng J, Zhang Y, Wang K, Jin H . Analysis of CT and MRI Combined Examination for the Diagnosis of Acute Cerebral Infarction. J Coll Physicians Surg Pak. 2019; 29(9):898-899. DOI: 10.29271/jcpsp.2019.09.898. View

Kim H, Shin H, Jeong H, An H, Kim N, Chae H . Reduced IL-2 but elevated IL-4, IL-6, and IgE serum levels in patients with cerebral infarction during the acute stage. J Mol Neurosci. 2000; 14(3):191-6. DOI: 10.1385/JMN:14:3:191. View

Zhou J, Zhang J . Identification of miRNA-21 and miRNA-24 in plasma as potential early stage markers of acute cerebral infarction. Mol Med Rep. 2014; 10(2):971-6. DOI: 10.3892/mmr.2014.2245. View

Wang J, Lin M, Ren H, Yu Z, Guo T, Gu B . Expression and Clinical Significance of Serum miR-497 in Patients with Acute Cerebral Infarction. Clin Lab. 2019; 65(4). DOI: 10.7754/Clin.Lab.2018.181001. View

Hu Y, Xu R, He Y, Zhao Z, Mao X, Lin L . Downregulation of microRNA‑106a‑5p alleviates ox‑LDL‑mediated endothelial cell injury by targeting STAT3. Mol Med Rep. 2020; 22(2):783-791. PMC: 7339537. DOI: 10.3892/mmr.2020.11147. View

Mamlouk M, Tsai F, Drachman D, Stradling D, Hasso A . Cerebral thromboembolism: value of susceptibility-weighted imaging in the initial diagnosis of acute infarction. Neuroradiol J. 2013; 25(1):45-56. DOI: 10.1177/197140091202500107. View

10.

Yang Y, Feng L, Shi Q, Wang L, Hou L, Wang R . Silencing of long non-coding RNA LINC00958 inhibits head and neck squamous cell carcinoma progression and AKT/mTOR signaling pathway by targeting miR-106a-5p. Eur Rev Med Pharmacol Sci. 2020; 24(16):8408-8417. DOI: 10.26355/eurrev_202008_22638. View

11.

Rahimirad S, Navaderi M, Alaei S, Sanati M . Identification of hsa-miR-106a-5p as an impact agent on promotion of multiple sclerosis using multi-step data analysis. Neurol Sci. 2021; 42(9):3791-3799. DOI: 10.1007/s10072-020-04979-1. View

12.

Lu T, Rothenberg M . MicroRNA. J Allergy Clin Immunol. 2017; 141(4):1202-1207. PMC: 5889965. DOI: 10.1016/j.jaci.2017.08.034. View

13.

Xiang Q, Wang J, Wang T, Zuo H . Combination of baicalein and miR-106a-5p mimics significantly alleviates IL-1β-induced inflammatory injury in CHON-001 cells. Exp Ther Med. 2021; 21(4):345. PMC: 7903477. DOI: 10.3892/etm.2021.9776. View

14.

Qin L, Li W, Huang Y, Lu F, Li S, Yang H . PTX3 expression in the plasma of elderly ACI patients and its relationship with severity and prognosis of the disease. Eur Rev Med Pharmacol Sci. 2016; 20(19):4112-4118. View

15.

Majd M, Hosseini A, Ghaedi K, Kiani-Esfahani A, Tanhaei S, Shiralian-Esfahani H . MiR-9-5p and miR-106a-5p dysregulated in CD4 T-cells of multiple sclerosis patients and targeted essential factors of T helper17/regulatory T-cells differentiation. Iran J Basic Med Sci. 2018; 21(3):277-283. PMC: 5817171. DOI: 10.22038/ijbms.2018.25382.6275. View

16.

Yan Z, Fu B, He D, Zhang Y, Liu J, Zhang X . The relationship between oxidized low-density lipoprotein and related ratio and acute cerebral infarction. Medicine (Baltimore). 2018; 97(39):e12642. PMC: 6181483. DOI: 10.1097/MD.0000000000012642. View

17.

Kim S, Lee J, Park S, Jang H, Lim E, Chang S . Plasma B-type natriuretic peptide level in patients with acute cerebral infarction according to infarction subtype and infarction volume. Int J Med Sci. 2013; 10(1):103-9. PMC: 3534883. DOI: 10.7150/ijms.5005. View

18.

Backes C, Meese E, Keller A . Specific miRNA Disease Biomarkers in Blood, Serum and Plasma: Challenges and Prospects. Mol Diagn Ther. 2016; 20(6):509-518. DOI: 10.1007/s40291-016-0221-4. View

19.

Dowling M, Quinn C, Plumb P, Rogers Z, Rollins N, Koral K . Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease. Blood. 2012; 120(19):3891-7. PMC: 3496951. DOI: 10.1182/blood-2012-01-406314. View

20.

Chalos V, van der Ende N, Lingsma H, Mulder M, Venema E, Dijkland S . National Institutes of Health Stroke Scale: An Alternative Primary Outcome Measure for Trials of Acute Treatment for Ischemic Stroke. Stroke. 2019; 51(1):282-290. PMC: 6924951. DOI: 10.1161/STROKEAHA.119.026791. View